Too many white cells—TAM, JMML, or something else?

Author:

Satty Alexandra1,Stieglitz Elliot2,Kucine Nicole3

Affiliation:

1. 1 Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY

2. 2 Department of Pediatrics, Benioff Children’s Hospitals, University of California San Francisco, San Francisco, CA

3. 3 Department of Pediatrics, Weill Cornell Medicine, New York, NY

Abstract

Abstract Leukocytosis is a common finding in pediatric patients, and the differential diagnosis can be broad, including benign reactive leukocytosis and malignant myeloproliferative disorders. Transient abnormal myelopoiesis is a myeloproliferative disorder that occurs in young infants with constitutional trisomy 21 and somatic GATA1 mutations. Most patients are observed, but outcomes span the spectrum from spontaneous resolution to life-threatening complications. Juvenile myelomonocytic leukemia is a highly aggressive myeloproliferative disorder associated with altered RAS-pathway signaling that occurs in infants and young children. Treatment typically involves hematopoietic stem cell transplantation, but certain patients can be observed. Early recognition of these and other myeloproliferative disorders is important and requires a clinician to be aware of these diagnoses and have a clear understanding of their presentations. This paper discusses the presentation and evaluation of leukocytosis when myeloproliferative disorders are part of the differential and reviews different concepts regarding treatment strategies.

Publisher

American Society of Hematology

Subject

Hematology

Reference45 articles.

1. Nathan and Oski’s Hematology and Oncology of Infancy and Childhood (8th ed);Orkin,2014

2. Lanzkowsky’s manual of pediatric hematology and oncology (6th ed);Lanzkowsky,2016

3. Risks of leukaemia and solid tumours in individuals with Down's syndrome;Hasle;Lancet,2000

4. Leukemia risk in a cohort of 3.9 million children with and without Down Syndrome;Marlow;J Pediatr,2021

5. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms;Khoury;Leukemia,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3